For Immediate Release Contact email@example.com
November 27, 2011
CHICAGO, Nov. 27, 2011 – Toshiba America Medical Systems, Inc., launched the AplioTM 500 ultrasound system, enabling clinicians to diagnose like never before, using the most advanced visualization tools in the industry. The Aplio 500 ultrasound is 510(k) cleared and displayed at the Radiological Society of North America (RSNA) annual meeting in Chicago, Nov. 27 – Dec. 2, 2011 (Booth #5634, South Hall).
Aplio 500 combines advanced visualization capabilities, workflow automation tools and superior ergonomics for more accurate diagnoses and improved departmental efficiency. The system is backed by Toshiba’s Reliance Program, the industry’s best warranty/technology protection program.
Toshiba’s Aplio 500 comes optional with Fly Thru and Smart Fusion, two advanced features unmatched in the industry:
• Fly Thru: This industry-first technology revolutionizes ultrasound diagnosis using 3D volume rendering to “fly through” interiors of ducts and vessels for better exploration of lesions and masses, and to assist in planning interventional procedures. Fly Thru gives clinicians an entirely new perspective of 3D imaging.
• Smart Fusion: Shows both CT and ultrasound images side-by-side on a single screen. Smart Fusion syncs the two images, helping to locate hard-to-find lesions and aiding in ultrasound-guided biopsy without additional CT scans. Toshiba’s Smart Fusion is easy to use, with the most intuitive user set-up available.
“Toshiba’s Fly Thru is a unique adaptation of 3D/4D ultrasound, providing an inside-out view of anatomical structures, which is a different way of looking at the body using ultrasound,” said Dr. Edward G. Grant, professor and chairman, Department of Radiology, USC Keck School of Medicine, who evaluated the technology.
The Aplio 500 delivers picture-perfect images powered by Toshiba’s unique technologies, including Tissue Specific Optimization (TSO), Precision Imaging, Differential Tissue Harmonics (D-THI), Advanced Dynamic FlowTM (ADF) and ApliPureTM+. Toshiba’s iStyleTM+ Productivity Suite, which offers a full range of workflow automation tools combined with superior ergonomics that include a 19 inch LCD screen with a handle for easy repositioning, adjustable console for convenient patient access, and lighter weight and smaller footprint, makes the Aplio 500 system the ideal system for today’s busy ultrasound department.
“Toshiba’s Aplio 500 allows clinicians to use ultrasound in new ways for faster, more accurate diagnoses achieved non-invasively,” said Tomohiro Hasegawa, director, Ultrasound Business Unit, Toshiba. “With more than 40 years of ultrasound experience, Aplio 500 is another example of Toshiba’s commitment to developing exceptional technology and supporting it through unmatched customer service.”
With headquarters in Tustin, Calif., Toshiba America Medical Systems (TAMS) markets, sells, distributes and services diagnostic imaging systems, and coordinates clinical diagnostic imaging research for all modalities in the United States. For more information, visit the TAMS website at www.medical.toshiba.com.
Toshiba Medical Systems Corporation is a leading worldwide provider of medical diagnostic imaging systems and comprehensive medical solutions, such as CT, X-ray and vascular, ultrasound, nuclear medicine, and MRI systems, as well as information systems for medical institutions. Toshiba Medical Systems Corporation has been providing medical products for over 80 years. Toshiba Medical Systems Corporation is a wholly owned subsidiary of Toshiba.
Toshiba is a diversified manufacturer and marketer of advanced electronic and electrical products, spanning digital products, such as LCD TVs, notebook PCs and hard disc drives; electronic devices and components, such as semiconductors; social infrastructure systems, including power generation systems, and home appliances. Toshiba was founded in 1875, and today operates a global network of more than 490 companies, with 203,000 employees worldwide and annual sales surpassing 6.3 trillion yen (US$77 billion).